@article{4348764d9e0a43f586aa4f1ae077af53,
title = "Comparison of statistical approaches dealing with time-dependent confounding in drug effectiveness studies",
abstract = "In longitudinal studies, if the time-dependent covariates are affected by the past treatment, time-dependent confounding may be present. For a time-to-event response, marginal structural Cox models are frequently used to deal with such confounding. To avoid some of the problems of fitting marginal structural Cox model, the sequential Cox approach has been suggested as an alternative. Although the estimation mechanisms are different, both approaches claim to estimate the causal effect of treatment by appropriately adjusting for time-dependent confounding. We carry out simulation studies to assess the suitability of the sequential Cox approach for analyzing time-to-event data in the presence of a time-dependent covariate that may or may not be a time-dependent confounder. Results from these simulations revealed that the sequential Cox approach is not as effective as marginal structural Cox model in addressing the time-dependent confounding. The sequential Cox approach was also found to be inadequate in the presence of a time-dependent covariate. We propose a modified version of the sequential Cox approach that correctly estimates the treatment effect in both of the above scenarios. All approaches are applied to investigate the impact of beta-interferon treatment in delaying disability progression in the British Columbia Multiple Sclerosis cohort (1995–2008).",
keywords = "Bias (epidemiology), causality, confounding factors (epidemiology), epidemiologic methods, inverse probability weighting, longitudinal studies, models, survival analysis",
author = "{The BeAMS study group} and Karim, {Mohammad Ehsanul} and John Petkau and Paul Gustafson and Platt, {Robert W.} and Helen Tremlett and A. Shirani and Y. Zhao and C. Evans and E. Kingwell and {van der Kop}, {M. L.} and J. Oger",
note = "Funding Information: The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: MEK has received accommodation costs from the endMS Research and Training Network (2011, 2012), Statistical Society of Canada (2016) to present at conferences, and from Pacific Institute for the Mathematical Sciences (2013), The Canadian Statistical Sciences Institute (2016) to attend workshops. Over the past three years, JP has received consulting fees and/or fees for service on Data Safety Monitoring Boards from EMD Serono, Myelin Research Foundation and Novartis. PG has received consulting fees from Biogen to serve on an advisory board. RWP has received fees for service for consulting from Abbvie, Amgen, and Searchlight Pharma, for teaching from Novartis, and for scientific steering committee membership from Pfizer. HT has received speaker honoraria and/or travel expenses to attend conferences from the Consortium of MS Centres (2013), the National MS Society (2012, 2014, 2016), Teva Pharmaceuticals (2011), ECTRIMS (2011, 2012, 2013, 2014, 2015, 2016), UK MS Trust (2011), the Chesapeake Health Education Program, US Veterans Affairs (2012), Novartis Canada (2012), Biogen Idec (2014), American Academy of Neurology (2013, 2014, 2015, 2016). All speaker honoraria are either declined or donated to an MS charity or to an unrestricted grant for use by her research group. YZ declares no conflicts of interest. AS has received travel grants to present at and attend conferences from the endMS Research and Training Network (2010, 2011), ECTRIMS (2010, 2011), and the Consortium of MS Centres (2012). EK has had travel and accommodation costs covered to present at and attend conferences from the endMS Research and Training Network (2008, 2011), the International Society for Pharmacoepidemiology (2010, 2013) and Bayer Schering Pharma (2010). CE has received travel grants to present and attend conferences from the endMS Research and Training Network (2011), and the European Committee for Treatment and Research in MS (2011). MLvdK declares no conflicts of interest. Over the past five years, JO has received speaker honoraria, consulting fees, travel grants and/or research grants and/or educational grants from Aventis, Bayer, Biogen-Idec, BioMS, Corixa, Genentech, Novartis, Serono, Shering, Talecris and Teva-neurosciences. JO receives fees for services from Bayer, from Novartis and from Biogen Idec to serve on advisory committees. Funding Information: The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by a studentship from the Multiple Sclerosis (MS) Society of Canada (MEK), by a postdoctoral fellowship from the Canadian Network for Observational Drug Effect Studies (CNODES) (MEK) and by a grant from the National Multiple Sclerosis Society (RG 4202-A-2, PI: HT) and the Canadian Institutes of Health Research (MOP-93646, PI: HT). JP holds research grants from the National MS Society, and the Natural Sciences and Engineering Research Council of Canada. PG is supported by the Natural Sciences and Engineering Research Council of Canada. RWP holds the Albert Boehringer I Chair in Pharmacoepidemiology and is supported in part by a National Scholar (Chercheur-national) of the Fonds de R{\'e}cherche du Qu{\'e}bec-Sant{\'e} (FQR-S) and is a member of the Research Institute of the McGill University Health Centre, which is supported by core funds from FQR-S. HT is supported by the Canada Research Chair Program and currently receives research support from the National Multiple Sclerosis Society, the Canadian Institutes of Health Research, the Multiple Sclerosis Society of Canada, and the Multiple Sclerosis Scientific Research Foundation. In addition, in the last five years HT has received research support from the Multiple Sclerosis Society of Canada (Don Paty Career Development Award), the Michael Smith Foundation for Health Research (Scholar Award), and the UK MS Trust. YZ receives research funding from the Canadian Institutes of Health Research, the MS Society of Canada, and the National MS Society. AS was funded through a Postdoctoral Fellowship from the MS Society of Canada, and grants from the Canadian Institutes of Health Research (MOP-93646; PI¼H.T.) and the National MS Society (RG 4202-A-2; PI¼H.T.). EK was supported by Postdoctoral Fellowships from the Michael Smith Foundation for Health Research and the MS Society of Canada. CE was funded through grants from the Canadian Institutes of Health Research (MOP-93646; PI¼H.T.) and the National MS Society (RG 4202-A-2; PI¼HT), and the Michael Smith Foundation for Health Research. M.L.v.d.K. is supported by a Canadian Institutes of Health Research Doctoral Award—Doctoral Foreign Study Award (October 2012), offered in partnership with the Canadian Institutes of Health Research (CIHR) Strategy for Patient-Oriented Research, and the CIHR HIV/AIDS Research Initiative. JO receives support from the Christopher Foundation and the University of British Columbia (UBC). Over the past five years Dr Oger has received speaker honoraria, consulting fees, travel grants and/or research grants and/or educational grants of less than $5000 each from Bayer, Biogen-Idec, BioMS, Glaxo-Smith-Klein, Novartis, Merck-Serono, Talecris, and Teva-neurosciences. Dr Oger has received fees for services from Bayer and from Biogen Idec to serve on advisory committees. Publisher Copyright: {\textcopyright} 2016, {\textcopyright} The Author(s) 2016.",
year = "2018",
month = jun,
day = "1",
doi = "10.1177/0962280216668554",
language = "English (US)",
volume = "27",
pages = "1709--1722",
journal = "Statistical Methods in Medical Research",
issn = "0962-2802",
publisher = "SAGE Publications Ltd",
number = "6",
}